跳至主要内容
临床试验/NCT01412047
NCT01412047已完成不适用

A Post Marketing, Multi-Center, Trial to Measure Human Anti-Human Antibodies (HAHA) to Soliris (Eculizumab) in Patients With Paroxysmal Nocturnal Hemoglobinuria

Alexion Pharmaceuticals, Inc.7 个研究点 分布在 3 个国家目标入组 75 人开始时间: 2012年3月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
75
试验地点
7
主要终点
To summarize the proportion of patients with neutralizing HAHA antibodies.

研究概览

简要总结

How does long term treatment with Soliris affect HAHA in PNH patients?

详细描述

To determine the long term effect of Soliris (eculizumab) treatment on the presence of human anti-human antibodies (HAHA) in Paroxysmal Nocturnal Hemoglobinuria (PNH) patients.

研究设计

研究类型
Observational
观察模型
Other
时间视角
Prospective

入排标准

性别
All
接受健康志愿者

入选标准

  • PNH patients who previously participated in study E05-001;
  • Patients who have an eculizumab naive serum sample for comparison;
  • Patients who currently used commerical Soliris;
  • Patients who are willing and able to gie written informed consent.

排除标准

  • There are no exclusion criteria for this study.

结局指标

主要结局

To summarize the proportion of patients with neutralizing HAHA antibodies.

时间窗: Six (6) months

次要结局

  • To summarize the proportion of patients with non-neutralizing HAHA antibodies.(Six (6) months)
  • To summarize the proportion of patients with increased hemolysis in setting of neutralizing HAHA antibodies.(Six (6) months)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (7)

Loading locations...

相似试验

Paroxysmal Nocturnal Hemoglobinuria Human Anti-Human... | 临床试验